Clin2
NCT07253181Possibly a fitRecruiting

Stroke clot-busting drug before transfer for artery clearing

Acute Ischemic StrokeLarge Vessel OcclusionTransportation of Patients

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests whether giving a clot-busting drug (tenecteplase) before transferring you to a hospital that can do a procedure to remove the clot improves outcomes for people who had a stroke up to 24 hours earlier. You may qualify if you have a blockage in a large artery in the front of your brain and can still get the procedure.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
572 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 or older.
  • Your stroke symptoms started between 4.5 and 24 hours before treatment.
  • You had a stroke caused by a blockage in a large artery in the front part of your brain.
  • You were able to do daily activities without help before the stroke.
  • A brain scan shows a certain pattern that indicates you might benefit from this treatment.
  • You are planned to be transferred for a procedure to remove the clot.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07748039Not yet recruiting· Phase 3
Comparing two clot-busting drugs before clot removal for acute stroke

This trial compares two clot-dissolving medications (tenecteplase and reteplase) given before a procedure to remove a large clot from a brain artery. It aims to see which drug works better for people who have had an acute ischemic stroke and are eligible for both treatments.

Beijing, Beijing Municipality
NCT07203625Recruiting· Phase 4
Tenecteplase before transfer for basilar artery stroke

This trial tests if a clot-busting drug called Tenecteplase helps people with a severe type of stroke in the back of the brain (basilar artery occlusion) when given 4.5 to 24 hours after symptoms start. Patients will then be moved to a hospital that can remove the clot. The goal is to see if the drug improves recovery.

Beijing
NCT06781385Enrolling by invitation· Phase 2
Tenecteplase after clot removal for severe stroke

This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.

Charlotte, North Carolina
NCT07302854Recruiting· Phase 2/Phase 3
Clot-busting medicine for medium vessel strokes

This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.

Wuhan, Hubei
NCT07727395Recruiting· Phase 3
Clot-busting drug after successful clot removal for stroke

This trial tests whether giving a clot-busting drug (alteplase) directly into the brain artery after a successful clot removal improves recovery in people with severe stroke. It is for patients who have had a thrombectomy and still have a large blocked artery in the front of the brain.

An Giang
NCT07092709Recruiting· Phase 3
Tenecteplase for stroke patients who recently took blood thinners

This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.

Guangzhou, Guangdong

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.